Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 10NIH 3INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Melanoma 11Carcinoma, Renal Cell 8Lymphoma 7Neoplasm Metastasis 6Nasopharyngeal Carcinoma 6Lung Neoplasms 6Hematologic Neoplasms 5Glioblastoma 5Anus Neoplasms 5Rectal Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Leukemia, Myeloid, Acute 4Hodgkin Disease 4Glioma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Basal Cell 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma, Kaposi 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3HIV Infections 3Gliosarcoma 3Esophageal Neoplasms 3

Interventions

Cyclophosphamide 42Rituximab 40Vincristine 31Doxorubicin 29Prednisone 28Etoposide 27Filgrastim 22Peripheral Blood Stem Cell Transplantation 16Radiotherapy 12Ifosfamide 12Cytarabine 12Magnetic Resonance Spectroscopy 10Methotrexate 9Lenalidomide 8Cyclosporine 8Bortezomib 8fludarabine phosphate 7Vorinostat 7Specimen Handling 7Cisplatin 7Carboplatin 7tanespimycin 6ibrutinib 6Melphalan 6Gemcitabine 6Biopsy 6oblimersen 5alvocidib 5aldesleukin 5Oxaliplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Lymphoma, Large B-Cell, Diffuse × Nivolumab × Clear all
NCT05272384 2026-05-13

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Recruiting
32 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT03484819 2025-03-03

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
12 enrolled 13 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡